Head-To-Head Comparison: BioLargo (BLGO) and Its Rivals

BioLargo (NASDAQ:BLGO) is one of 34 public companies in the “Chemicals & allied products” industry, but how does it weigh in compared to its rivals? We will compare BioLargo to similar businesses based on the strength of its earnings, dividends, analyst recommendations, institutional ownership, risk, profitability and valuation.

Analyst Ratings

This is a breakdown of recent ratings and recommmendations for BioLargo and its rivals, as reported by MarketBeat.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
BioLargo	0	0	0	0	N/A
BioLargo Competitors	139	1280	1596	46	2.51

As a group, “Chemicals & allied products” companies have a potential upside of 7.17%. Given BioLargo’s rivals higher possible upside, analysts plainly believe BioLargo has less favorable growth aspects than its rivals.

Profitability

This table compares BioLargo and its rivals’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
BioLargo	-16.53%	-58.35%	-32.12%
BioLargo Competitors	-568.74%	5.73%	-0.15%

Insider & Institutional Ownership

0.0% of BioLargo shares are held by institutional investors. Comparatively, 68.4% of shares of all “Chemicals & allied products” companies are held by institutional investors. 20.3% of BioLargo shares are held by insiders. Comparatively, 10.1% of shares of all “Chemicals & allied products” companies are held by insiders. Strong institutional ownership is an indication that large money managers, hedge funds and endowments believe a company will outperform the market over the long term.

Valuation and Earnings

This table compares BioLargo and its rivals top-line revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Net Income	Price/Earnings Ratio
BioLargo	$12.23 million	-$3.50 million	-12.09
BioLargo Competitors	$6.67 billion	$204.21 million	-30.93

BioLargo’s rivals have higher revenue and earnings than BioLargo. BioLargo is trading at a higher price-to-earnings ratio than its rivals, indicating that it is currently more expensive than other companies in its industry.

Risk & Volatility

BioLargo has a beta of 0.18, meaning that its share price is 82% less volatile than the S&P 500. Comparatively, BioLargo’s rivals have a beta of 1.78, meaning that their average share price is 78% more volatile than the S&P 500.

Summary

BioLargo rivals beat BioLargo on 7 of the 10 factors compared.

About BioLargo

BioLargo, Inc. invents, develops, and commercializes various platform technologies. Its technologies solve challenging environmental problems comprising per – and polyfluoroalkyl substances (PFAS) water contamination, advanced water and wastewater treatment, industrial odor and volatile organic compounds control, air quality control, infection control, and myriad environmental remediation. The company provides full-service environmental engineering services. BioLargo, Inc. was incorporated in 1991 and is based in Westminster, California.